Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Comparison of mean days of wound healing across different wound types for wounds healed in more than 3 months durations (2022 and 2023). by Heba Tallah Mohammed (2822432)

Subjects:

Comparison of mean days of wound healing across different wound types for wounds healed in less than 3 months durations (2022 and 2023). by Heba Tallah Mohammed (2822432)

Subjects:

Mean mesenteric, retroperitoneal, pericardial, and total visceral adipose tissue weights (in grams) upon completion of the experiment. by Elsie D. Oduor (22521785)

Subjects:

a-d. Difference in (a) probing depth; (b) clinical attachment level; (c) bleeding on probing, and (d) plaque index values between baseline and six months after treatment using syst... by Iva Milinkovic (22331710)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”

Model effects of receiving kindness on reduced stress and well-being mediated by institutional identity. by K. Kanoho Hosoda (19929050)

Subjects:

Model effects of giving kindness on reduced stress and well-being mediated by institutional identity. by K. Kanoho Hosoda (19929050)

Subjects: